clinical trial · NCT00718484
A Study of Palifosfamide Tris Plus Doxorubicin Versus Doxorubicin in Unresectable or Metastatic Soft-tissue Sarcoma
Alaunos Therapeutics·phase2·completed·n = 67
Soft Tissue SarcomaPalifosfamide Tris and DoxorubicinDoxorubicin
brief summary
This is a randomized, controlled trial to evaluate the clinical benefit of palifosfamide tris administered with doxorubicin in combination, compared with single-agent doxorubicin administered in subjects diagnosed with unresectable or metastatic soft-tissue sarcoma (STS). Subjects who meet the entry criteria will be randomized into 1 of 2 arms: either to receive palifosfamide tris plus doxorubicin or treatment with single-agent doxorubicin. Subjects will be anthracyclin naïve.
started
Sep 3, 2008
primary completion
Sep 20, 2010
completion
Sep 20, 2011
last updated
Sep 29, 2026
official title
A Phase II Multicenter, Parallel Group, Randomized Study of Palifosfamide Tris Plus Doxorubicin Versus Doxorubicin in Subjects With Unresectable or Metastatic Soft-tissue Sarcoma
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol